Vera Therapeutics, Inc. Stock News

Vera Therapeutics (VERA) prices its public offering of 4,993,067 shares at a price of $15.00 per share

Vera Therapeutics was downgraded by Zacks Investment Research from a buy rating to a hold rating in a report released on Tuesday, Zacks.com reports. According to Zacks

Vera Therapeutics (VERA) commenced a public offering to issue and sell 4M class A shares. VERA expects to grant the underwriters a 30-day option to purchase up to an additional 600K class

Vera: Biotech With 3 Mid-Stage Programs With Potential For Success

Vera Therapeutics <> plans to begin a phase 3 trial of its lead product candidate atacicept in lupus nephritis ((LN)). The company said it received positive feedback from the U.S

Vera Therapeutics Inc - Class A (VERA) shares closed this week 20.9% lower than it did at the end of last week. The stock is currently down 20.9% year-to-date, up 83.8% over the past 12 months, and up 83.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Shares traded as high as $29.20 and as low as $20.28 this week.Shares closed 43.0% below its 52-week high and 87.1% above its 52-week low.Trading volume this week was 37.8% higher than the 10-day average and 14.9% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 7913.4% The company's stock price performance over the past 12 months beats the peer average by -1058.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Vera Therapeutics Inc - Class A (VERA) shares closed today 10.8% lower than it did at the end of yesterday. The stock is currently down 20.9% year-to-date, up 83.8% over the past 12 months, and up 83.8% over the past five years. Today, the Dow Jones Industrial Average fell 0.0%, and the S&P 500 fell 0.4%. Trading Activity Shares traded as high as $29.20 and as low as $20.28 this week.Shares closed 43.0% below its 52-week high and 87.1% above its 52-week low.Trading volume this week was 37.8% higher than the 10-day average and 14.9% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 7913.4% The company's stock price performance over the past 12 months beats the peer average by -1058.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

BRISBANE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments f

Vera Therapeutics (NASDAQ:VERA) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a report issued on Friday, Zacks.com reports. According to Zacks, Vera Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera Therapeutics Inc. is []

Ongoing Phase 2 clinical trial for MAU868 in kidney transplant patients; potential first-in-class

Vera Therapeutics (VERA) has been struggling lately, but the selling pressure may be coming to an end soon.

Pharmaceutical industry leader brings more than 30 years of quality, regulatory and manufacturing experience Pharmaceutical industry leader brings more than 30 years of quality, regulatory and manufacturing experience

Vera Therapeutics, Inc. (NASDAQ:VERA) shares fell 10.6% during mid-day trading on Wednesday . The company traded as low as $25.84 and last traded at $25.84. 1,131 shares were traded during mid-day trading, a decline of 98% from the average session volume of 54,135 shares. The stock had previously closed at $28.89. Separately, Zacks Investment Research []

Vera Therapeutics, Inc. (NASDAQ:VERA) Stock analysts at Jefferies Financial Group raised their FY2021 earnings per share estimates for Vera Therapeutics in a research note issued on Monday, December 6th. Jefferies Financial Group analyst M. Raycroft now anticipates that the company will post earnings per share of ($2.14) for the year, up from their previous []